



SCIENCE OF TODAY  
HOPE FOR TOMORROW

**MEXICO**

# Programa Final

20 y 21 de Mayo  
2016  
Crown Plaza WTC  
Ciudad de México



**Profesores Extranjeros**

Améndola Beatriz	Innovative Cancer Institute Miami, USA
Cárdenas Herbert	Perú
Gámez Haro Mauricio	Arizona, USA
Jimmy Hernández	Miami, USA
Linares Luis A	Guatemala, Guatemala

**Profesores Nacionales**

Astudillo Horacio	Nanopharmacia
Ayala Hernández Juan Ramón	Hospital Dalinde
Bayardo López Luis Héctor	CMN de Occidente, Gdl. Jal.
Bautista Hernández Yicel	Hospital General de México
Chávez Jessica	Hospital de Oncología, CMN, Siglo XXI
De la Mata Dolores	Hospital ABC
De la Peña Cuauhtémoc	Hospital Christus Muguerza Mty. NL.
Félix Leyva Armando	CMN Siglo XXI IMSS
Flores Castro Jesús Manuel	Instituto Nacional de Cancerología
Garay Villar Ónix	Hospital de Oncología, CMN Siglo XXI
Garza Garza Ernesto	UMAE 25 IMSS Mty. NL
Hinojosa Gómez José	Hospital ABC
Huerta Bahena Judith	FUCAM
León Arceo Pedro Rubén	UMAE 25 IMSS Mty, NL
Maldonado Magos Federico	Instituto Nacional de Cancerología
Martell Guerrero Ramón Jesús	CMN 20 de Noviembre
Mota García Aída	Instituto Nacional de Cancerología
Moyaho Ismael	Radioterapia Guadalupe, Puebla, Pue.
Núñez Guardado Gabriela	CMN 20 de Noviembre
Poitevin Adela	Hospital Médica Sur
Rodríguez Ramírez Saúl	Tumores de Colon y Recto, CMN Siglo XXI
Rosales Pérez Samuel	Hospital de Oncología, CMN Siglo XXI
Ruesga Daniel	Hospital General de México
Souto del Bosque Miguel Ángel	UMAE 25 Mty. NL
Tokunaga Jorge	Tijuana BCN
Villavicencio Quejeiro Michelle	CMN 20 de Noviembre
Zamora Varaona-Moreno Jesús	Instituto Nacional de Cancerología

<b>REGISTRO</b>			
7:30			
8:30	<b>INAUGURACIÓN</b> <b>Presidium: Dra Julia Saenz Frias, Dra Nimbe Barroso, Dra Aída Mota, Dr Ismael Moyaho, Dra Adela Poitevin, Lic. David Erazo, Lic. Jorge Garcia,</b>		
9:00	<b>Breast Cancer</b>	(Dr. Pedro León: Maestro de Ceremonias)	
			A Large Prospectively Designed Study of the DCIS Score: Recurrence Risk After Local Excision For Ductal Carcinoma In Situ Patients With and Without Irradiation
9:10			Long-term Toxicity and Outcomes of Hypofractionated Radiation Therapy With an Incorporated Boost for Early-Stage Breast Cancer
9:20			Accelerated Partial Breast Irradiation Using Sole Interstitial Multicatheter Brachytherapy vs Whole Breast Irradiation for Early Breast Cancer: 5-year Results of a Randomized Phase III Trial – Part I: Local Control and Survival Results
9:30			NRG Oncology/RTOG 1014: 1-Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal Partial-Breast Reirradiation (PBrI) for In-Breast Recurrence
9:40	Locoregional Failure Rates Are Low After Mastectomy in a Modern Cohort of Patients with T1-T2 Tumors With 1-3 Pathologically Involved Lymph Nodes	Dra. Yicel Bautista Hospital General de México	
9:50	Experiencia en Braquiterapia de Alta Tasa de Dosis en Próstata con Cobalto-60	Dr. Herbert Cárdenas Perú	
10:40	<b>COFFEE BREAK</b>		
11:10	<b>Física</b>	Fisico Ernesto Eliher Garza Garza UMAE 25 Mty NL	
			Dose-Response Relationship for Stereotactic Ablative Body Radiation Therapy Associated Airway Collapse
11:20			Validation of a Knowledge-Based Automated Planning System in Cervical Cancer As a Clinical Trial Quality System
11:30			Radiomic Analysis of FDG-PET Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With SBRT
11:40	Mesa Redonda Mama, Pulmón y Físcos		
12:00	“Simposium Varian – Impact of Advanced Radiation Technology in Latin America”		
12:40	<b>Lung</b>	Dr. Federico Maldonado Magos Instituto Nacional de Cancerologia	
			Comparison of 3-D Conformal and Intensity Modulated Radiation Therapy Outcomes for Locally Advanced Non-Small Cell Lung Cancer in NRG Oncology/RTOG 0617
12:50			Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypothesis of Radiation
13:00			The Lung Metastasis Risk (LMR) Signature: A Prognostic Genomic Biomarker Predicting Distant Failure Among Stage I Adenocarcinoma Patients Following Local Therapy
13:10			Predicting Overall Survival Following Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model
13:20	NRG Oncology/RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation (PCI) Alone To PCI and Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)		

13:30	Seguridad del Paciente	Results of Voluntary Error Reporting in Radiation Oncology Treatment Delivery From a Multipractice Setting From 2005 to 2014	Físico Daniel Ruesga Hospital General de México
13:40		A Validated Nomogram to Predict Near Miss and Safety Incidents in Radiation Oncology: A Multi-institutional Effort	
13:50		Validation of a Causal Factor Taxonomy Used in Radiation Oncology Incident Learning	
14:00		A Quantitative Assessment of the Utility of Safety Barriers	
14:10	<b>Receso / Box Lunch</b>		
14:40	Cuidados Paliativos	Comparison of Patient Reported Outcomes With Single Versus Multiple Fraction Palliative Radiation Therapy for Complicated Bone Metastasis	Dra. Jessica Chávez Hospital de Oncología, Centro Médico Nacional, Siglo XXI
14:50		Efficacy of Spine Radiosurgery for Oligometastatic Spine Disease: A Large Institutional Experience	
15:00		Impact of a Dedicated Palliative Radiation Oncology Service on the Use of Single-Fraction and Hypofractionated Radiation Therapy Among Patients With Bone Metastases	
15:10		Long-term Survivors of an SBRT Dose-Escalation Study for Oligometastases: Clinical and Molecular Markers	
15:20		Outcomes After Whole-Brain Reirradiation for Multiple Brain Metastases: Total Dose Is Associated With Improved Overall Survival	
15:30	Linfoma / Leucemia	Does the Risk of Cardiovascular Disease Plateau Following Mediastinal Irradiation: A Review of Hodgkin Lymphoma Survivors With Over 30 Years of Follow-up	Dra. Adela Poitevin Chacón. Hospital Médica Sur
15:40		Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non Hodgkin Lymphoma	
15:50		Patterns of Care and Survival Outcomes Examining Radiation Therapy for Advanced Hodgkin Lymphoma	
16:00		Early-stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: The Impact of Radiation Therapy on Overall Survival	
16:10		Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease	
16:20		Mesa Redonda: Seg Paciente, C Paliativos y Linfoma Leucemia	Dra. Beatriz Améndola y Dr. Mauricio Gámez
16:40	Educational Session	Rectal Cancer Clinical Practice Statement: One Size Does Not Fit All.	Luis A. Linares MD, FACRO , Hope Radiotherapy Center
			Dr. Saúl Rodríguez Ramírez, Tumores de Colon y Recto, CMN Siglo XXI
			Moderador Dr. Cuauhtemoc de la Peña



# Sábado 21 de Mayo

8:00	<b>Bienvenida : Dr Ismael Moyaho</b>	
8:10	Modulo de Cabeza y Cuello	Comparing the Survival, Recurrence, and Toxicities Between Surgery With Adjuvant Therapy Versus Surgery Alone for Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma
8:20		Cetuximab-based Bioradiation Therapy Is Associated With Higher Rates of Distant Metastases Than Platinum-based Chemoradiation Therapy in Human Papillomavirus–Positive Oropharyngeal Cancer
8:30		Risk Stratification for Relapse in Human Papillomavirus–Unrelated Oropharyngeal Carcinoma Treated With Definitive Radiation Therapy With or Without Chemotherapy
8:40		The Value of Adding Chemotherapy to Intensity Modulated Radiation Therapy for Stage II Nasopharyngeal Carcinoma: A Multicenter Phase 2 Study
8:50		Radiation Plus Concurrent Nimotuzumab Versus Cisplatin-Based Chemotherapy in Locally Advanced Nasopharyngeal Cancer: An Interim Analysis of a Phase 3 Randomized Clinical Trial
9:00		Individualized Super Selective Nodal Radiation Therapy for cN0 Head and Neck Squamous Cell Carcinoma Patients Based on Sentinel Node(s) Identification: A Prospective Phase 2 Study of SPECT/CT-guided volume de-escalation
9:10		Mesa Redonda
9:25	Radiobiología	High-throughput Transcriptomic Analysis Nominates Proteasomal Genes as Age Specific Biomarkers and Therapeutic Targets in Prostate Cancer
9:35		Radiation Induced CD8 T-Lymphocyte Apoptosis As a Predictor of Late Toxicity After Radiation Therapy: Results of the Prospective Multicenter French Trial
9:45		Systematic Investigation of Genetic Vulnerabilities Across Cancer Cell Lines Reveals Lineage Specific Radiotherapeutic Determinants
9:55		Response, Resistance, and Biomarkers for Radiation and Immune Checkpoint Blockade
10:05		Mesa Redonda ( Dr. Astudillo como panelista )
10:20	<b>COFFEE BREAK</b>	

Dra. Michelle Villavicencio Quejeiro  
CMN 20 de Noviembre

Mauricio Gamez Haro  
MD, Arizona, USA

Dr. Luis Linares

Dr. Jesus Manuel Flores Castro Instituto Nacional de Cancerologia.

Dra. Adela Poitevin

**10:20 COFFEE BREAK**

<b>10:50</b>	<b>Genitourinario</b>	Quality of Life Outcomes: ASCENDE-RT * a Multicentre Randomized Trial of Radiation Therapy for Prostate Cancer	Dr. Armando Félix Leyva CMN Siglo XXI IMSS
<b>11:00</b>		Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer	
<b>11:10</b>		Management and Outcomes of Clinical Stage II A/B Seminoma: Results From the National Cancer Data Base	
<b>11:20</b>	<b>Genitourinario</b>	Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG Oncology/RTOG 9202	Dr. José Hinojosa Gómez Hospital ABC
<b>11:30</b>		Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma: Final Results of the European Groupe d'Etude des Tumeurs Uro-Génitales (GETUG-01) Randomized Study	
<b>11:40</b>		Contemporary Update of a Multi-institutional Predictive Nomogram for Salvage Radiation Therapy After Prostatectomy	
<b>11:50</b>		Mesa Redonda,	
<b>11:50</b>			Dra. Judith Huerta Bahena
<b>12:05</b>	<b>Modulo de Ginecología</b>	Phase III RCT of Postoperative Adjuvant Conventional Radiation Therapy (3DCRT) Versus IGIMRT for Reducing Late Bowel Toxicity in Cervical Cancer (PARCER) (NCT01279135/CTRI2012/120349): Results of Interim Analyses	Dr. Ramón Jesús Martell Guerrero CMN 20 de Nov.
<b>12:15</b>		Adjuvant Intensity Modulated Radiation Therapy With Concurrent Paclitaxel and Cisplatin in Cervical Cancer Patients With High Risk Factors: A Phase 2 Trial	
<b>12:25</b>		Salvage Versus Adjuvant Radiation Treatment for Women With Early-Stage Endometrial Carcinoma: A Matched Analysis	
<b>12:35</b>		Metformin Use Is Associated With Lower Cervical Cancer-Specific Mortality	Dra. Onix Garay Villar Hospital de Oncología, CMN Siglo XXI
<b>12:45</b>		Adjuvant Radiation is Essential in the Management of Pelvis-Limited Stage III Endometrial Carcinoma	
<b>12:55</b>	Impact of Hyperglycemia in Patients With Cervical Cancer Treated With Definitive Chemoradiation on Overall Survival and Locoregional Control		

13:05	Receso / Box Lunch	
13:35	Sistema Nervioso Central	The Effect of Gene Mutations on Survival in Patients With Adenocarcinoma of the Lung Following the Development of Brain Metastases
13:45		A Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery (SRS) for Large Resection Cavities of Brain Metastases
13:55		Comparing Preoperative Stereotactic Radiosurgery (SRS) to Postoperative SRS for Resectable Brain Metastases
14:05		International Consensus Contouring Guidelines for Postoperative Spine Stereotactic Body Radiation Therapy (SBRT)
14:15		Delayed Contrast MRI for Differentiating Brain Tumors From Treatment Effects in Conventional and Combined Treatments
14:25		A Phase 2 Study of Temozolomide in the Treatment of Adult Patients With Supratentorial Low-grade Glioma
14:35		Mesa Redonda Ginecología y SNC
14:55	GASTROINTESTINAL	Involved-field Irradiation vs Elective Nodal Irradiation for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Comparative Interim Analysis of Clinical Outcomes and Toxicities (NCT01551589, CSWOG 003)
15:05		Pathological Response Is a Marker But Not a Cause of Good Prognosis in Rectal Cancer: 15-year Follow-up of the Lyon R90-01 Randomized Trial
15:15		Phase 2 Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: ECOG 3204
15:25		Preoperative Chemoradiation With a Simultaneous Integrated Boost Compared to Regular Preoperative Chemoradiation for Locally Advanced Rectal Cancer: Interim Analysis of a Randomized Phase 2 Trial (NCT02195141)
15:35	Mesa Redonda	
15:50	<b>COMENTARIOS FINALES DEL DIA y Clausura</b>	

Dra. Gabriela Nuñez Guardado  
CMN 20 de Noviembre

Dr. Pedro Ruben Leon Arceo  
UMAE 25 IMSS  
Mty, NL

Dra Aída Mota / Dr Héctor Bayardo

Dr Miguel Ángel Souto del Bosque  
UMAE 25  
Mty NL

Dr. Samuel Rosales Pérez, Hospital de Oncología, CMN Siglo XXI

Dr. Jesus Zamora

Dr. Luis Linares





SCIENCE OF TODAY  
HOPE FOR TOMORROW  
**MEXICO**

